Mirum Pharmaceuticals (NASDAQ:MIRM) executives said the rare disease company is entering a catalyst-heavy period, with recent positive clinical updates, ongoing commercial momentum for LIVMARLI and additional business development activity expanding its portfolio.
Speaking at RBC Capital Markets’ 20
NEW YORK — The euphoric "small-cap comeback" that defined the opening weeks of 2026 came to a grinding halt on Thursday. The Russell 2000 index, the primary barometer for American small-cap health, plummeted 1.9% on March 5, 2026, marking its sharpest single-day decline of the year. The sell-off, triggered by
Penn Capital initiated a position in ACM Research, which supplies cleaning and plating tools used in advanced semiconductor manufacturing. As AI-driven chip designs grow more complex, precision equipment becomes more valuable, but demand remains tied to export controls and capital spending cycles.
Date: January 13, 2026 Introduction Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) has reached a critical inflection point, evolving from a speculative clinical-stage biotech into a commercial-stage powerhouse in the rare liver disease sector. As of early 2026, the company stands as a beacon of growth in the biotechnology landscape, recently surpassing annual revenue targets and achieving [...]
